BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 9437561)

  • 21. Levonorgestrel implant use among adolescents.
    Mashburn M
    J Pediatr Health Care; 1994; 8(6):255-60. PubMed ID: 7799199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endometrial angiogenic response in Norplant users.
    Subakir SB; Hadisaputra W; Handoyo AE; Affandi B
    Hum Reprod; 1996 Oct; 11 Suppl 2():51-5. PubMed ID: 8982746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New concepts in contraception: Norplant subdermal implant.
    Lynn MM; Holdcroft C
    Nurse Pract; 1992 Mar; 17(3):85-9. PubMed ID: 1565306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Norplant implants in a New York City clinic population.
    Gerber S; Westhoff C; Lopez M; Gordon L
    Contraception; 1994 Jun; 49(6):557-64. PubMed ID: 8070260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the acceptability of Norplant contraceptive in four patient populations.
    Dugoff L; Jones OW; Allen-Davis J; Hurst BS; Schlaff WD
    Contraception; 1995 Jul; 52(1):45-9. PubMed ID: 8521714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Norplant implants among Thai women in Bangkok.
    Chompootaweep S; Kochagarn E; Sirisumpan S; Tang-usaha J; Theppitaksak B; Dusitsin N
    Contraception; 1996 Jan; 53(1):33-6. PubMed ID: 8631187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subjective perception of bleeding and serum ferritin concentration in long-term users of Norplant.
    Faundes A; Tejada AS; Brache V; Alvarez F
    Contraception; 1987 Feb; 35(2):189-96. PubMed ID: 3109804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
    Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
    Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subdermal contraceptive implants.
    Peralta O; Diaz S; Croxatto H
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):223-6. PubMed ID: 7626459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with side effects and health risks associated with Norplant implant use in adolescents.
    Rosenthal SL; Biro FM; Kollar LM; Hillard PJ; Rauh JL
    Contraception; 1995 Nov; 52(5):283-5. PubMed ID: 8585884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative assessment of the effects of subdermal levonorgestrel implant system and long acting progestogen injection method on lipid metabolism.
    Anwar M; Soejono SK; Maruo T; Abdullah N
    Asia Oceania J Obstet Gynaecol; 1994 Mar; 20(1):53-8. PubMed ID: 8172528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with elective Norplant removal in black and white women.
    Opara JU; Ernst FA; Gaskin H; Smith L; Nevels HV
    J Natl Med Assoc; 1997 Apr; 89(4):237-40. PubMed ID: 9145628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Norplant-2 subdermal contraceptive system: experience in Taiwan.
    Lee TY; Yang YS; Tseng LH; Ko TM; Hsu MC; Chuang SM
    J Formos Med Assoc; 1993 May; 92(5):446-50. PubMed ID: 8104598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics and experiences of American women electing for early removal of contraceptive implants.
    Frank ML; Ditmore JR; Ilegbodu AE; Bateman L; Poindexter AN
    Contraception; 1995 Sep; 52(3):159-65. PubMed ID: 7587187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuation rates of long-acting methods of contraception. A comparative study of Norplant implants and intrauterine devices.
    Fleming D; Davie J; Glasier A
    Contraception; 1998 Jan; 57(1):19-21. PubMed ID: 9554246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.